Resumen
Oncolytic viruses (OVs) preferentially infect and kill cancer cells. Additionally, OV-induced immune responses subvert cancer-associated immunosuppression and promote antitumor immunity. We have recently demonstrated that the complementation of oncolytic virotherapy with gemcitabine accentuates its immunostimulatory effects, hence exerting superior antineoplastic activity.
| Idioma original | English |
|---|---|
| Número de artículo | e27622 |
| Publicación | OncoImmunology |
| Volumen | 3 |
| N.º | 1 |
| DOI | |
| Estado | Published - 2014 |
Nota bibliográfica
Funding Information:This work was supported by the research grants from the Canadian Institute of Health Research (CIHR), Terry Fox Research
ASJC Scopus Subject Areas
- Immunology and Allergy
- Immunology
- Oncology
ODS de las Naciones Unidas
Este resultado contribuye a los siguientes Objetivos de Desarrollo Sostenible
Acceder al documento
Otros archivos y enlaces
Huella
Profundice en los temas de investigación de 'Two is better than one: Complementing oncolytic virotherapy with gemcitabine to potentiate antitumor immune responses'. En conjunto forman una huella única.Citar esto
Gujar, S. A., Clements, D., & Lee, P. W. K. (2014). Two is better than one: Complementing oncolytic virotherapy with gemcitabine to potentiate antitumor immune responses. OncoImmunology, 3(1), Artículo e27622. https://doi.org/10.4161/onci.27622